Well, the existing data do not show that. Patients often stop using GLP-1s within a year for a variety of reasons, including cost, meeting their goal weight or gastrointestinal side effects
Watch for low blood sugar If youre taking a GLP-1 receptor agonist along with insulin or other diabetes medications, your blood sugar could dip too low
Se si considerano tutti i pazienti randomizzati, compresi quelli che hanno interrotto la terapia (la misura pi vicina alla realt clinica), la perdita di peso media stata del 13,6% a 64 settimane , contro il 2,2% del placebo
Research notes that technical complexity, substantial capital requirements, and the need for specialized expertise are driving pharma firms to outsource GLP-1 peptide production to CDMOs ( [14] )